The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with hras mutations (AIM-HN) and the impact of hras mutations on response to first line systemic therapies for HNSCC (SEQ-HN).
 
Robert I. Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Eisai; Genentech; GlaxoSmithKline; Immunomic Therapeutics; Loxo; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Kura Oncology (Inst); Merck (Inst); Pfizer (Inst); VentiRx (Inst)
 
Kevin Joseph Harrington
Honoraria - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst)
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Replimune (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Replimune (Inst)
 
Lisa F. Licitra
Consulting or Advisory Role - Amgen and Nanobiotics Sa; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Doxapharma; Eisai; GlaxoSmithKline; Incyte; Merck Serono; MSD; Nanobiotix; Novartis; Roche; SOBI
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Merck Serono; MSD
 
Amanda Psyrri
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Genesis Pharmaceuticals; Merck Serono; MSD Oncology; Pfizer; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer; Rakuten Medical
Research Funding - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Demo Pharmaceutical; Kura Oncology; Pfizer; Pharmathen; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Ipsen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; AstraZeneca
 
Nabil F. Saba
Honoraria - Aduro Biotech; Bristol-Myers Squibb; CUE Biopharma; Genentech/Roche; GlaxoSmithKline; Kura Oncology; Lilly; Merck; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck; Pfizer
Research Funding - Bristol-Myers Squibb; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Lilly; Merck; Pfizer
 
Natasa Rajicic
Consulting or Advisory Role - Kura Oncology
 
Binaifer Balsara
Employment - Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
 
Michael R. Kurman
Employment - Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
 
Catherine Rose Scholz
Employment - Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
Patents, Royalties, Other Intellectual Property - Kura Oncology
 
Antonio Gualberto
Employment - Kura Oncology
Leadership - Kura Oncology
Stock and Other Ownership Interests - Kura Oncology
Patents, Royalties, Other Intellectual Property - Kura Oncology
 
Alan Loh Ho
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; CureVac; CureVac; Eisai; Genzyme; Merck; Novartis; Regeneron; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck